DMN:FRA
Diamyd Medical AB
€ ०.०६१
arrow_upward
+०.१७%(+०.०००१०) 1D
नोभेम्बर १७, ०८:०५:२३ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.२६ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.२६ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
ChartMill
·
१ घण्टा पहिले
S&P 500 Stocks Gapping Down in Today's Session
TradingView
·
२ घण्टा पहिले
Wells Fargo sets 2027 S&P 500 year-end target at 8,200
qz.com
·
४ घण्टा पहिले
5 Nasdaq-linked stock indexes and how each differs from the S&P 500
Traders Union
·
२८ मिनेट पहिले
S&P 500 trades near AVWAP and key retracement lines, Chris Ciovacco notes
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB